REGIONAL AND INTRAREGIONAL CLUSTERS NOVUM RESEARCH PARK 1972

REGIONAL AND INTRAREGIONAL CLUSTERS

NOVUM RESEARCH PARK 1972 Huddinge University Hospital 1985 -91 Novum Research Foundations Center for Biotechnology Center for Nutrition & Toxicology Center for Structural Biochemistry Center for Oral Biology Founders: Stockholm County Council & Karolinska Institute Purpose: To create a biomedical center of excellence 1985 - R&D companies in and near Novum. Expanison of research Improvements of infrastructure (communications, hotel, shops) 1989 Novum Research Center 1997 - 02 2000 - University of Södertörn Planning for Novum Bio. City

NOVUM RESEARCH PARK A. D. 2002 A qualified environment for front-line research and for the establishment and growth of research-based companies Novum Research Foundations (4 foundations ~ 350 employees) biomedical basic research Departments & Centers of Research (~ 350 employees) Karolinska Institute, Huddinge University Hospital, Södertörn University biomedical & medical technology research Research Companies (20 companies, ~ 450 employees) Novum Business Development Group business counselling, strategic planning information & visitor’s service

NOVUM PRECLINICAL RESEARCH • • • Nuclear receptors Signal transduction Molecular genetics Molecular nutrition Molecular immunology Structural biochemistry

NOVUM CLINICAL RESEARCH • Cancer Osteoporosis • Metabolic disorders Alzheimer’s disease • Cellular therapy Virus infection • Gene therapy (Hepatitis)

NEIGHBOURS AND PARTNERS IN NOVUM RESEARCH PARK • HUDDINGE UNIVERSITY HOSPITAL • THE KAROLINSKA INSTITUTET MEDICAL SCHOOL • SÖDERTÖRN UNIVERSITY COLLEGE • SERVICE COMPANIES (about 25) ____________ Appr. 17. 000 personer (employees & students) working daily in the park area

BUSINESS COUNSELLING IN NOVUM • Patenting • Licensing • Business law • Market analysis • Business Planning • Financing

NOVUM’S RESEARCH COMPANIES Multinationals Astra. Zeneca Pain Control Research Baxter Medical Renal Function Research Sumitomo Pharmaceuticals Alzheimer’s disease

Novum’s Research Companies R&D specialists Karo Bio Receptor biology Medivir HIV & Herpes antivirals Tripep HIV antivirals Light. Up Technologies DNA probe technology /diagnostics Avaris Gene vector technolog Oxypharma Rheumatoid Arthritis

NOVUM’S RESEARCH COMPANIES Service & Technology providers • Cyber. Gene • Nova Snitt Analysis • Sci. Base • Innomed-Konsult Sequencing, genetic diagnostics Histology Impedance analysis of skin & mucosa Design of GMP facilities

NOVUM BIOCITY

NOVUM BIOCITY

NOVUM RESEARCH PARK

Nuclear Receptors Hormones or Metabolic Intermediates Changed Cell Function Protein Nuclear Receptor Target gene • Large family of receptors • Important drugs on the market • Validated drug targets • Bind hormones with high affinity • New technology and receptors offer improved treatments and new indications

LXR New Promising Target for Atherosclerosis • Upregulates cholesterol pump (ABCA 1) • Upregulates APO-E in macrophages • Upregulates 7 hydroxylase (cholesterol break down)

LXR Concept to Treat Atherosclerosis Drug compound Atherosclerosis stimulates LXR activity LXR stimulates synthesis of ABC 1 protein LXR + ABC 1 -protein Cell Treated blood vessel Tangier disease; non-functional ABC-1 leads to atherosclerosis ABC 1 removes harmful cholesterol

Karo Bio – Leader in Nuclear Receptor and Proteomics-Based Drug Discovery

Boehringer Ingelheim BMS Merck AHP Abbott Karo Bio AB Stockholm Karo Bio USA, Inc. Karo Bio, Inc. San Francisco Durham, NC Bayer AG GPC Biotech Nov. Immune S. A. Serono International Aventis

Business Concept Ø Develop pharmaceuticals for major markets Ø Be a leading company within the field of nuclear receptors and proteomics-based drug discovery Ø Conduct clinical development and marketing through partners and licensees Ø Finance operations through partnerships

Revenue Model of Karo Bio Up-front payment Target identification Research funding Drug discovery Pre-clinical development R&D milestones Clinical development Royalty on sales Market

Strategic Position KARO BIO Scientific network Karolinska Insitutet UCSF Duke University of Bochum Sahlgrenska Hospital University of York … Partners Abbott Laboratories Bristol-Myers Squibb Merck & Co, Inc. Aventis …

Nuclear Receptor Project Portfolio Target and indication Drug discovery Preclinical Development validation LXR AHP ER Merck 2 1 1 2 …. . . C l i n i c a l D e v e l o p m e n t…. . . Phase III THR Obesity BMS GR Diabetes Abbott R Prostate cancer /KB MR Heart failure /KB GR Inflammation /KB THR Cardiac. THR 015/Cardiac arrhythmia /KB arrhythmia/KB THR Glaucoma/KB Anti-microbials/KB THR KB 2611/ Skin atrophy /KB NDA

Karo Bio has a diverse nuclear receptor research portfolio Disease area Atherosclerosis Drug discovery Preclinical development Clinical development Phase III NDA/ Market 100 MUSD + Royalties Oestrogen receptor 80 MUSD + Royalties Type II diabetes 56 MUSD + Royalties Obesity 40 MUSD + Royalties Karo Bio has four profitable nuclear receptor collaborations in potential block-buster areas

Några reflektioner kring ett nytt paradigm för medicinsk och bioteknisk forskning • Avståndet mellan laboratoriebänken och patientens säng har minskat betydligt och minskar allt snabbare i takt med den nya molekylärbiologiska forskningens landvinningar • Enda sättet att föra över forskningsresultat från lab. bänken till patienten går via patentering och kommersialisering • Den nutida laboratorieforskaren har ett etiskt imperativ att börja arbeta i denna riktning (modern tillämpning av den Hippokratiska eden!)

Några reflektioner…… (forts. ) • Det nya paradigmet för medicinsk/naturvetenskaplig forskning består i en trestegsraket, akademi, SMEs samt stora företag, där de två första stegen bör samlokaliseras under ett tak • I detta cluster kommer nya forskningsstrategier och forskningstekniker att växa fram samtidigt som nya utbildningslinjer med kombinationer av bioteknik, medicin, ekonomi, juridik, etik mm kommer att utvecklas • Allt detta betyder effektivare forskning, större konkurrenskraft i ett internationellt perspektiv samt bättre ekonomi för Sverige